Log in

Relevant bibliographies by topics / Long-acting antipsychotics / Journal articles

To see the other types of publications on this topic, follow the link: Long-acting antipsychotics.

Journal articles on the topic 'Long-acting antipsychotics'

Author: Grafiati

Published: 7 June 2025

Last updated: 17 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Long-acting antipsychotics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Aparasu, Rajender R., and Sanika Rege. "Long-Acting Injectable Antipsychotic Medications in Schizophrenia Management." International Journal of Pharmaceutical Sciences and Nanotechnology 10, no. 6 (2016): 3507–11. http://dx.doi.org/10.37285/ijpsn.2017.10.6.2.

Full text

Abstract:

Antipsychotic medications are indicated for the treatment of schizophrenia and other psychiatric disorders including bipolar disorder. However, oral antipsychotics are associated with a number of issues including poor treatment adherence. Long Acting Injectable (LAI) antipsychotics were designed to address these issues with oral antipsychotics. LAI antipsychotics offer several advantages including less frequent dose administration, better adherence and tolerability, and relapse prevention, which in turn help in improving patients’ quality of life. Recent development of atypical antipsychotics

APA, Harvard, Vancouver, ISO, and other styles

2

Joo, Eun-Jeong, Kyu Young Lee, Seong Hoon Jeong, and Yong Sik Kim. "Breakthrough Psychosis and Long-Acting Injectable Antipsychotics." Korean Journal of Schizophrenia Research 26, no. 1 (2023): 1–11. http://dx.doi.org/10.16946/kjsr.2023.26.1.1.

Full text

Abstract:

“Breakthrough” of psychosis despite good compliance of antipsychotics medication for a long time is a major obstacle to the treatment of schizophrenia, whether the mechanism is caused by dopamine hypersensitivity or insufficient dose of antipsychotics. Researchers advocating “Dopamine Supersensitivity Psychosis” (DSP) emphasize to avoid excessive inhibition of dopamine 2 receptors from the beginning of treatment. On the other hand, researchers advocating “Breakthrough psychosis on Antipsychotic Maintenance Medication” (BAMM) in which psychosis recurs due to insufficient medication despite cont

APA, Harvard, Vancouver, ISO, and other styles

3

Sathienluckana, Thanompong, Pornyupa Tiangpattanawong, Karnpreena Chaiyasukthananoan, Pannapat Jittayanan, Hathaipat Sawetwangsing, and Punyawee Puchsaka. "Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia." Schizophrenia Research and Treatment 2021 (November 25, 2021): 1–6. http://dx.doi.org/10.1155/2021/8403986.

Full text

Abstract:

Background. Long-acting injectable (LAI) antipsychotics are used as a monotherapy in patients with schizophrenia. However, the combination of LAI and oral antipsychotics is commonly used in clinical practice, despite there being very limited studies investigating the efficacy and safety of this combination compared with LAI antipsychotic monotherapy. Objective. To study the efficacy and safety of LAI antipsychotic monotherapy compared with the combination of LAI and oral antipsychotics in patients with schizophrenia. Methods. This study was a retrospective cohort study, which classified eligib

APA, Harvard, Vancouver, ISO, and other styles

4

Jarema, Marek. "Two in one: simultaneous use of two long-acting antipsychotics in schizophrenia." Pharmacotherapy in Psychiatry and Neurology 37, no. 1 (2021): 45–51. http://dx.doi.org/10.33450/fpn.2021.03.001.

Full text

Abstract:

Objectives. This paper aims to review the literature regarding the possible simultaneous use of two long-acting antipsychotics in the treatment of schizophrenia. Selected literature review. Despite using the appropriate dose in antipsychotic treatment and continuing it for the necessary period, it happens that such treatment may be considered ineffective. In such a case, to supplement the clinical effect of antipsychotics, the addition of a second antipsychotic medication, mood stabiliser, or an antidepressant may be considered. If the inadequate response to the treatment results from poor med

APA, Harvard, Vancouver, ISO, and other styles

5

Olagunju, Andrew T., Scott R. Clark, and Bernhard T. Baune. "Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome." Australian & New Zealand Journal of Psychiatry 53, no. 6 (2019): 509–27. http://dx.doi.org/10.1177/0004867419837358.

Full text

Abstract:

Objective: Impairment in psychosocial function is common in schizophrenia. Long-acting injectable atypical antipsychotics are thought to enhance psychosocial function by boosting adherence. However, no systematic review has examined the effects of long-acting injectable atypical antipsychotics on psychosocial function in clinical trials. Methods: We searched major databases including Medline/PubMed, PsychINFO, EMBASE, CINAHL, Scopus, Web of Science, Cochrane Central Register of Controlled Trials and Clinical Trial Registries for randomised controlled trials that compared long-acting injectable

APA, Harvard, Vancouver, ISO, and other styles

6

Johnston, Karen, Jennifer Kern Sliwa, Cynthia A. Bossie, Edward Kim, and Barbara J. Limandri. "Long-Acting Injectable Antipsychotics." Journal of Psychosocial Nursing and Mental Health Services 57, no. 11 (2019): 5. http://dx.doi.org/10.3928/02793695-20191016-02.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Correll, Christoph U., and John Lauriello. "Long-Acting Injectable Antipsychotics." Journal of Clinical Psychiatry 79, no. 1 (2018): AL17017WC1C. http://dx.doi.org/10.4088/jcp.al17017wc1c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Morrissette, Debbi A., and Stephen M. Stahl. "Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment." CNS Spectrums 17, s1 (2012): 10–21. http://dx.doi.org/10.1017/s1092852912000739.

Full text

Abstract:

Antipsychotics are the mainstay of treatment for patients with schizophrenia. However, these medications only work if they are taken and perhaps work best if they are taken for longer periods of time than seen in typical research trials. Here we explore the idea of “time as a drug” by reviewing the data showing the potential benefits of long-term antipsychotic use. We also discuss the utility of depot antipsychotic formulations for improving the chances of attaining long-term therapeutic results.

APA, Harvard, Vancouver, ISO, and other styles

9

Ifteni, P., and A. Teodorescu. "Schizophrenia long-acting antipsychotics initiation index (SLAAII)." European Psychiatry 64, S1 (2021): S813. http://dx.doi.org/10.1192/j.eurpsy.2021.2149.

Full text

Abstract:

IntroductionBackground In individuals with schizophrenia, long-acting injectable antipsychotics (LAIs) have been shown to be beneficial in preventing relapse. An important issue in these individuals is poor medication adherence, which can negatively affect outcomes. Although currently underutilized in comparison with oral antipsychotics, LAIs can be an important treatment option for addressing the high rates of poor adherence to medication in individuals with schizophrenia. There is a lack of published evidence and treatment guidelines on optimal strategies for the initiation of treatment with

APA, Harvard, Vancouver, ISO, and other styles

10

Citrome, Leslie. "Long-acting injectable antipsychotics: what, when, and how." CNS Spectrums 26, no. 2 (2021): 118–29. http://dx.doi.org/10.1017/s1092852921000249.

Full text

Abstract:

AbstractCurrent guidelines for the treatment of patients with schizophrenia advocate that patients receive treatment with a long-acting injectable (LAI) antipsychotic medication if they prefer such treatment or if they have a history of poor or uncertain adherence. Available LAI formulations in the United States include first-generation antipsychotics (fluphenazine decanoate and haloperidol decanoate), risperidone/paliperidone containing products (risperidone microspheres, paliperidone palmitate, and risperidone subcutaneous), aripiprazole containing products (aripiprazole monohydrate and arip

APA, Harvard, Vancouver, ISO, and other styles

11

Gómez, L. Pérez, A. Gónzalez Fernández, D. F. Frías Ortíz, et al. "Long-acting injectable antipsychotics: Diagnostics and patient profile." European Psychiatry 33, S1 (2016): S616. http://dx.doi.org/10.1016/j.eurpsy.2016.01.2305.

Full text

Abstract:

IntroductionLong-acting injectable antipsychotics (LAIs) were developed in the sixties with the purpose of improving schizophrenia maintenance treatment. The main advantages are: the ability to ensure compliance, maintaining stable plasma concentrations and allowing better clinical management of drug therapy. Long-acting atypical injectable antipsychotics start to develop in the late nineties. Currently, they are the most widely used depot treatment for severe mental illness.ObjectiveChecking patient profile and diagnosis where we use LAIs.MethodsReview of 217 patients treated with LAIs in CSM

APA, Harvard, Vancouver, ISO, and other styles

12

UYAR, Betül, Abdullah ATLI, and Derya GÜL BİLEN. "Bipolar bozukluk tip I hastalarının tedavisinde uzun etkili antipsikotiklerin klinik kullanımı." Cukurova Medical Journal 47, no. 2 (2022): 844–51. http://dx.doi.org/10.17826/cumj.1089059.

Full text

Abstract:

Purpose: This study aims to determine the usage frequency of long-acting injectable antipsychotics among bipolar disorder type 1 patients who presented to the Dicle University Faculty of Medicine Psychiatry and Mental Health outpatient clinic, the clinical characteristics of these patients, and the preferences of clinicians about these agents.  Materials and Methods: Our study included 111 patients older than 18 years old with bipolar disorder. The ’data of the patients were retrospectively obtained from electronic data records. The data were recorded in the data collection form prepared

APA, Harvard, Vancouver, ISO, and other styles

13

Sanjeevi, Sujatha, Muadz Mohd Zubir, Rose Bennett, Piril Cevikel, Natasya Nor, and Angela Cocoman. "Retrospective chart review of metabolic screening of patients receiving clozapine and long-acting injectable antipsychotic medications." British Journal of Mental Health Nursing 13, no. 1 (2024): 1–13. http://dx.doi.org/10.12968/bjmh.2022.0014.

Full text

Abstract:

Background/Aims Individuals treated with antipsychotic medications are at risk of developing metabolic syndrome, negatively impacting the quality of life among patients with severe mental illness. The aim of this study was to examine metabolic screening data and determine the prevalence of metabolic syndrome among those who were prescribed clozapine and long-acting injectable antipsychotics. Methods This retrospective chart review looked at 307 patient records who were prescribed clozapine and long-acting injectable antipsychotics as part of a service improvement initiative. Results The preval

APA, Harvard, Vancouver, ISO, and other styles

14

Toja-Camba, Francisco José, Nerea Gesto-Antelo, Olalla Maroñas, et al. "Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics." Pharmaceutics 13, no. 7 (2021): 935. http://dx.doi.org/10.3390/pharmaceutics13070935.

Full text

Abstract:

Over the last two decades, pharmacogenetics and pharmacokinetics have been increasingly used in clinical practice in Psychiatry due to the high variability regarding response and side effects of antipsychotic drugs. Specifically, long-acting injectable (LAI) antipsychotics have different pharmacokinetic profile than oral formulations due to their sustained release characteristics. In addition, most of these drugs are metabolized by CYP2D6, whose interindividual genetic variability results in different metabolizer status and, consequently, into different plasma concentrations of the drugs. In t

APA, Harvard, Vancouver, ISO, and other styles

15

Pejčić, Ana V., Srdjan M. Stefanović, Miloš N. Milosavljević, et al. "Outcomes of long-acting injectable antipsychotics use in pregnancy: A literature review." World Journal of Psychiatry 14, no. 4 (2024): 582–99. http://dx.doi.org/10.5498/wjp.v14.i4.582.

Full text

Abstract:

BACKGROUND Women with a history of serious psychotic disorders are at increased risk of disease relapse during pregnancy. Long-acting injectable (LAI) antipsychotics have been widely used to improve adherence and prevent relapse in patients with various severe psychotic disorders, but there is a lack of high-quality data from previous research on the safety of LAI antipsychotics during pregnancy. AIM To summarize relevant data on maternal, pregnancy, neonatal, and developmental outcomes from published cases of LAI antipsychotic use in pregnancy. METHODS A literature search was performed throug

APA, Harvard, Vancouver, ISO, and other styles

16

Lasser, Robert A., Cynthia A. Bossie, Georges M. Gharabawi, and Martin Turner. "Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone." European Psychiatry 19, no. 4 (2004): 219–25. http://dx.doi.org/10.1016/j.eurpsy.2003.11.007.

Full text

Abstract:

AbstractBackgroundConventional depot antipsychotics can provide constant pharmacologic treatment, eliminating partial compliance and reducing relapse risk. Atypical antipsychotics, have improved clinical profiles but require daily dosing, compromising their overall effectiveness. As oral risperidone provides safety and efficacy benefits over oral haloperidol, improvements may be realized by replacing conventional with atypical agents in long-acting therapy. This report examines 50-weeks of long-acting risperidone therapy in patients previously stabilized with conventional depot antipsychotics.

APA, Harvard, Vancouver, ISO, and other styles

17

Kane, John M. "Utilization of Long-Acting Antipsychotic Medication in Patient Care." CNS Spectrums 11, S14 (2006): 1–8. http://dx.doi.org/10.1017/s1092852900025852.

Full text

Abstract:

AbstractSchizophrenia is a complex disorder characterized by a broad spectrum of psychopathology. Aggressive efforts to bring the patient into remission should begin immediately after the first episode. Consequences of non-remission include poor prognosis, psychiatric and general medical complications, treatment resistance, and death from medical comorbidities and suicide. Prevention of relapse following remission is critical to the well-being and optimal functioning of patients with schizophrenia.The key to optimizing patients' outcomes is to ensure a patient's long-term continuation on medic

APA, Harvard, Vancouver, ISO, and other styles

18

Bosanac, Peter, and David Jonathan Castle. "Why are long-acting injectable antipsychotics still underused?" BJPsych Advances 21, no. 2 (2015): 98–105. http://dx.doi.org/10.1192/apt.bp.114.013565.

Full text

Abstract:

Summary‘Depot antipsychotics' (‘long-acting injectable antipsychotic medications' or LAIs) are underused in the treatment of schizophrenia (including first episodes) and, possibly, of schizophrenia with comorbid substance use disorders. Patients' and clinicians' beliefs and attitudes, and service barriers, affect best practice and evidence-based care in LAI prescription. Poor medication adherence is a key reason for LAI prescription, but patients receiving LAIs may still relapse or experience significant side-effects. Patients' and clinicians' attitudes towards antipsychotic medication, as wel

APA, Harvard, Vancouver, ISO, and other styles

19

Mitchell, Shalina, and Prabin Gautam. "Procyclidine Use in Long-Acting Injectable Antipsychotics." BJPsych Open 11, S1 (2025): S237. https://doi.org/10.1192/bjo.2025.10592.

Full text

Abstract:

Aims: Following a Serious Untoward Incident investigation into a patient death where blood tests revealed procyclidine overdose, significant concerns emerged regarding procyclidine prescribing practices. A notable discrepancy was identified between the Summary of Product Characteristics and British National Formulary regarding maximum daily procyclidine dosing, with evidence of 40 mg daily doses being administered. This raised questions about prescribing practices, particularly in patients receiving long-acting injectable antipsychotics. The incident highlighted the need to evaluate current pr

APA, Harvard, Vancouver, ISO, and other styles

20

Knopf, Alison. "Why some teens may need long‐acting injectables." Brown University Child and Adolescent Behavior Letter 41, no. 5 (2025): 5–6. https://doi.org/10.1002/cbl.30867.

Full text

Abstract:

The Food and Drug Administration (FDA) has not approved long‐acting injectable (LAI) antipsychotic medications for patients under age 18, but researchers have found that for some teens, prescribing these medications off‐label is helpful. This is particularly true in teens with bipolar disorder who forget or don't want to take their oral medications, according to the researchers, who found that the LAI antipsychotics were effective, and recommend more FDA trials.

APA, Harvard, Vancouver, ISO, and other styles

21

Thiem, Helena, Here Folkerts, and Lukas Völkel. "Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia." Gesundheitsökonomie & Qualitätsmanagement 25, no. 03 (2020): 170–78. http://dx.doi.org/10.1055/a-1167-6057.

Full text

Abstract:

Abstract Aim This research aims to compare the efficacy and direct costs of short-acting oral antipsychotics and aripiprazole once-monthly (AOM) in the context of the treatment of patients with schizophrenia based on real-world data in Germany. Method Results are based on a single-armed, retrospective, non-interventional pre-post comparison study evaluating data from 132 patients with schizophrenia before and after switching from oral antipsychotics to AOM treatment (6 months each). Socio-demographics, as well as parameters of indication, efficacy and resource consumption were analyzed and sta

APA, Harvard, Vancouver, ISO, and other styles

22

Paton, Carol, and Chike Okocha. "Risperidone long-acting injection: the first 50 patients." Psychiatric Bulletin 28, no. 1 (2004): 12–14. http://dx.doi.org/10.1192/pb.28.1.12.

Full text

Abstract:

Aims and MethodRisperidone long-acting injection (RLAI) is the first atypical antipsychotic drug to be available in a ‘depot’ formulation. The evidence base underpinning its use is small. We sought to evaluate its early use in clinical practice by a naturalistic follow-up study of the first 50 patients to be prescribed RLAI in one National Health Service Trust.ResultsAt 6 months, 54% of patients had achieved at least minimal improvement, 4% were unchanged, 24% failed to comply, and 18% fared poorly and were switched to alternative antipsychotics. The attrition rate at 6 months was 42%. Supplem

APA, Harvard, Vancouver, ISO, and other styles

23

Liang, Chih-Sung, Tung-Ping Su, Ming-Hsien Hsieh, et al. "Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia." Journal of Personalized Medicine 11, no. 11 (2021): 1198. http://dx.doi.org/10.3390/jpm11111198.

Full text

Abstract:

In the last decade, long-acting injectable antipsychotics has been widely used in schizophrenia. Aripiprazole long-acting once-monthly (AOM) is the only long-acting dopamine partial agonist antipsychotic approved for schizophrenia; however, a literature search revealed no guidance on safely switching from oral and long-acting injectable antipsychotics to AOM. This study aimed to develop recommendations of AOM use based on existing data and expert consensus. A committee of 30 experts in psychopharmacology from major hospitals across Taiwan was invited. A modified Delphi method was conducted, co

APA, Harvard, Vancouver, ISO, and other styles

24

Taylor, David. "Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review." British Journal of Psychiatry 195, S52 (2009): s13—s19. http://dx.doi.org/10.1192/bjp.195.52.s13.

Full text

Abstract:

BackgroundDepot antipsychotics are widely used in clinical practice. Long-acting formulations of second-generation antipsychotics are now being developed and introduced.AimsTo review the pharmacology, pharmacokinetics and adverse effect profiles of currently available antipsychotic long-acting injections (LAIs).MethodThe psychopharmacological properties of first- and second-generation antipsychotic LAIs are reviewed using data available up to October 2008.ResultsFirst-generation antipsychotic (FGA) LAIs are associated with a high rate of acute and chronic movement disorders. Risperidone LAI is

APA, Harvard, Vancouver, ISO, and other styles

25

Kim, Seoyoung, and Euitae Kim. "Current advances in pharmacotherapy for schizophrenia." Journal of the Korean Medical Association 67, no. 2 (2024): 96–102. http://dx.doi.org/10.5124/jkma.2024.67.2.96.

Full text

Abstract:

Background: Schizophrenia is a complex psychiatric disorder characterized by hallucinations, delusions, and cognitive deficits, often leading to functional decline. Pharmacotherapy has long played a central role in schizophrenia management with our evolving understanding shaping the treatment.Current Concepts: Antipsychotic agents are the mainstay of the pharmacological treatment of schizophrenia. Although second-generation antipsychotics (atypical) reduce extrapyramidal side effects, they give rise to metabolic concerns. Personalized treatment, guided by the response and side effects of the p

APA, Harvard, Vancouver, ISO, and other styles

26

Ustohal, Libor. "Long-acting injectable antipsychotics in clinical practice." Klinická farmakologie a farmacie 31, no. 3 (2017): 10–15. http://dx.doi.org/10.36290/far.2017.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Haddad, Peter M., Mark Taylor, and Omair S. Niaz. "First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies." British Journal of Psychiatry 195, S52 (2009): s20—s28. http://dx.doi.org/10.1192/bjp.195.52.s20.

Full text

Abstract:

BackgroundAntipsychotic long-acting injections (LAIs) are often used in an attempt to improve medication adherence in people with schizophrenia.AimsTo compare first-generation antipsychotic long-acting injections (FGA–LAIs) with first- and second-generation oral antipsychotics in terms of clinical outcome.MethodSystematic literature review.ResultsA meta-analysis of randomised controlled trials (RCTs) showed no difference in relapse or tolerability between oral antipsychotics and FGA–LAIs but global improvement was twice as likely with FGA–LAIs. Four prospective observational studies were ident

APA, Harvard, Vancouver, ISO, and other styles

28

Paraschakis, A., and M. Papasaika. "Long-acting injectable antipsychotics during pregnancy: An update." European Psychiatry 64, S1 (2021): S834—S835. http://dx.doi.org/10.1192/j.eurpsy.2021.2204.

Full text

Abstract:

IntroductionLong-acting injectable (LAI) antipsychotics are related to proven compliance to treatment and more constant medication levels (hence the apparent lower side-effect burden).ObjectivesTo highlight the experience with LAI antipsychotic treatment during pregnancy.MethodsLiterature review.ResultsSeven cases are reported. A 35year old with schizophrenia received zuclopenthixole LAI (mostly 200mg/monthly) during both her pregnancies (of healthy girls born at weeks 39 and 40). A 35year old with schizophrenia was under risperidone LAI (25mg/2 weeks) and gave birth to a healthy girl at week

APA, Harvard, Vancouver, ISO, and other styles

29

Patel, R., E. Chesney, M. Taylor, D. Taylor, and P. McGuire. "Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?" Psychological Medicine 48, no. 10 (2017): 1616–23. http://dx.doi.org/10.1017/s0033291717003051.

Full text

Abstract:

AbstractBackgroundPaliperidone palmitate is one of the most widely prescribed long-acting injectable (LAI) antipsychotics in the UK. However, it is relatively expensive and there are few data comparing its effectiveness to that of other LAI antipsychotics. We sought to address this issue by analyzing a large anonymized electronic health record (EHR) dataset from patients treated with LAI antipsychotics.MethodsEHR data were obtained from 1281 patients in the South London and Maudsley NHS Foundation Trust (SLaM) who started treatment with a LAI antipsychotic between 1 April 2011 and 31 January 2

APA, Harvard, Vancouver, ISO, and other styles

30

Moxon-Holt, Megan, and Chris Todd. "Case Series Evaluating the Use of Combined Long Acting Injectable Antipsychotics in Three Patients Within Forensic Services." BJPsych Open 8, S1 (2022): S11. http://dx.doi.org/10.1192/bjo.2022.98.

Full text

Abstract:

AimsAntipsychotic polypharmacy is a relatively common practice, despite a lack of robust evidence. In 2018, the National Clinical Audit of Psychosis evaluated the treatment of 8000 patients with a diagnosis of schizophrenia or schizoaffective disorder, and found 10% were receiving non-clozapine antipsychotic polypharmacy. This included 432 patients receiving one oral & one long acting injectable (LAI) antipsychotic and 2 patients receiving two LAI antipsychotics. An audit within our service, found that 24 of 88 (27%) inpatients were receiving non-clozapine antipsychotic polypharmacy. Of th

APA, Harvard, Vancouver, ISO, and other styles

31

Robbins, Laura, Vinila Zachariah, Opeyemi Ikuewumi, and Raj Sambhi. "Long-Acting Antipsychotic Injections: Prescribing Practices Across BCUHB." BJPsych Open 11, S1 (2025): S210. https://doi.org/10.1192/bjo.2025.10533.

Full text

Abstract:

Aims: Our aims for this project were to examine how long-acting antipsychotics are prescribed in the various teams (both inpatient, community and specialist services) across BCUHB, with a view to identify any emerging trends, and to compare this with data on efficacy and cost-effectiveness obtained via a systematic search of the available literature.Methods: Data on depots prescribed across BCUHB was provided to us by the mental health pharmacy team for the year April 2023–March 2024. We extracted our points of interest from this data and demonstrated this graphically using Microsoft Excel.We

APA, Harvard, Vancouver, ISO, and other styles

32

Johnson, D. A. W. "Historical perspective on antipsychotic long-acting injections." British Journal of Psychiatry 195, S52 (2009): s7—s12. http://dx.doi.org/10.1192/bjp.195.52.s7.

Full text

Abstract:

BackgroundClinical experience has shown considerable potential benefits from long-term continuous medication for chronic or relapsing forms of schizophrenia. These benefits have not always been realised.AimsTo review the research literature in order to understand the problems of long-term medication and use of antipsychotic oral medication and long-acting injections (LAIs), and to place these in an historical context.MethodReview of literature.ResultsResearch showed that the potential success of LAI therapy depends on the quality of the follow-up service.ConclusionsFollowing the advent of seco

APA, Harvard, Vancouver, ISO, and other styles

33

Möller, H. J. "Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot." European Psychiatry 20, no. 5-6 (2005): 379–85. http://dx.doi.org/10.1016/j.eurpsy.2005.03.006.

Full text

Abstract:

AbstractRelapse is one of the key factors in the long-term outcome of schizophrenia. The consequences of relapse are diverse and often unpredictable, and the time to recovery and degree of recovery worsen with each successive relapse. There is now overwhelming evidence that advances in antipsychotic drug treatment have led to significant reductions in the rate of relapse. This review charts the developments that have taken place in antipsychotic therapy from the introduction of depot formulations, through atypical agents, to the development of the first long-acting atypical antipsychotic. Depo

APA, Harvard, Vancouver, ISO, and other styles

34

Modesitt, Taylor, Erica Kubascik, and Carol Ott. "Extent of use of long-acting injectable antipsychotics in children and adolescents within Indiana Medicaid." Mental Health Clinician 8, no. 5 (2018): 202–7. http://dx.doi.org/10.9740/mhc.2018.09.202.

Full text

Abstract:

Abstract Introduction: Oral formulations of the antipsychotics aripiprazole, asenapine, lurasidone, olanzapine, paliperidone, quetiapine, and risperidone are indicated for use in pediatrics for several diagnoses. Long-acting injectable (LAI) antipsychotics are of interest in this special population because they may be used due to convenience and desire to improve adherence, despite limited support in the literature. The primary intent of this study is to provide descriptive information on the use of paliperidone palmitate, risperidone microspheres, aripiprazole extended-release injection, and

APA, Harvard, Vancouver, ISO, and other styles

35

Marumoto, *Tatsuro, Hiroshi Horio, Hiroaki Kinoshita, et al. "FACTORS ASSOCIATED WITH CONTINUATION OF PALIPERIDONE PALMITATE 1-MONTH FORMULATION MONOTHERAPY IN PATIENTS WITH SCHIZOPHRENIA." International Journal of Neuropsychopharmacology 28, Supplement_1 (2025): i160—i161. https://doi.org/10.1093/ijnp/pyae059.277.

Full text

Abstract:

Abstract Background Schizophrenia often requires long-term treatment with antipsychotics. Paliperidone palmitate long-acting injection (PPLAI) is one of the advantageous options to maintain adherence, prevent relapse and hospitalization (Kishimoto et al., 2021; Tiihonen et al., 2017). In Japan, paliperidone palmitate 1-monthly (PP1M) and paliperidone palmitate 3-monthly (PP3M) have been approved, and the approved patient population for PP3M in Japan is limited to patients with schizophrenia who have been stabilized with PP1M monotherapy. Antipsychotic polypharmacy consisting of LAI and oral an

APA, Harvard, Vancouver, ISO, and other styles

36

Molina, I. Martínez, N. Gómez-Coronado Suárez de Venegas, and P. Blanco Ramón. "Reasons to choose a long acting antipsychotic and tolerability." European Psychiatry 41, S1 (2017): s822. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1604.

Full text

Abstract:

IntroductionAripiprazole depot is an atypical antipshycotic used to treat positive and negative symptoms of psychosis or acute mania.AimDescribe the reason why psychiatrists switch the current antipsychotic treatment on to aripiprazol depot, its tolerability and the reasons to stop aripiprazol depot treatment.MethodsDescriptive analysis based on a sample of 37 patients, aged 18–65 years, treated during one year with antipsychotics at two community mental health units.ResultsSwitching on to aripiprazole depot principal reasons: promote adherence (25%), persistence of symptoms (25%) and high lev

APA, Harvard, Vancouver, ISO, and other styles

37

Meyer, Jonathan M. "Understanding depot antipsychotics: an illustrated guide to kinetics." CNS Spectrums 18, s1 (2013): 55–68. http://dx.doi.org/10.1017/s1092852913000783.

Full text

Abstract:

Long-acting injectable (LAI) antipsychotics can have considerable advantages over oral medications for the management of patients with schizophrenia. Despite the high prevalence of treatment nonadherence with oral pharmacotherapy, LAI antipsychotics are significantly underutilized in this patient population. The availability of newer LAI antipsychotic preparations combined with a resurgent interest in the use of typical antipsychotics has rekindled awareness of the value of LAI medications. This article is intended to provide a visual understanding of the various kinetic profiles of LAI antips

APA, Harvard, Vancouver, ISO, and other styles

38

Chue, Pierre, and Robin Emsley. "Long-Acting Formulations of Atypical Antipsychotics." CNS Drugs 21, no. 6 (2007): 441–48. http://dx.doi.org/10.2165/00023210-200721060-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Miura, Gentaro, Fuminari Misawa, Yuko Kawade, Yasuo Fujii, Masaru Mimura, and Taishiro Kishimoto. "Long-Acting Injectables Versus Oral Antipsychotics." Journal of Clinical Psychopharmacology 39, no. 5 (2019): 441–45. http://dx.doi.org/10.1097/jcp.0000000000001082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Meyer, Jonathan M. "Converting oral to long-acting injectable antipsychotics: a guide for the perplexed." CNS Spectrums 22, S1 (2017): 14–28. http://dx.doi.org/10.1017/s1092852917000840.

Full text

Abstract:

There has been increasing recognition that antipsychotic nonadherence is common across all stages of schizophrenia, starting from the first episode. Moreover, numerous meta-analyses of the existing literature indicate superiority of long-acting injectable (LAI) over oral antipsychotics when one adjusts for the greater illness severity and duration among patients in LAI antipsychotic trials. The increasing availability of LAI antipsychotic options has raised interest in converting patients from oral medication; however, the successful transition from oral to the comparable LAI antipsychotic req

APA, Harvard, Vancouver, ISO, and other styles

41

Petric, Paula Simina, Andreea Teodorescu, Ana Aliana Miron, Mihnea Costin Manea, and Petru Ifteni. "Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics." American Journal of Therapeutics 31, no. 3 (2024): e219-e228. http://dx.doi.org/10.1097/mjt.0000000000001729.

Full text

Abstract:

Background: Patients with schizophrenia often face challenges related to cognitive function, affecting their daily functioning and overall quality of life. The choice of antipsychotic treatment may play a crucial role in determining cognitive outcomes. Study Question: Our study aimed to investigate whether there was a difference in cognitive ability between the patients with schizophrenia receiving oral antipsychotics (OAP) versus long-acting injectable antipsychotics (LAI-APs). Study Design: We conducted a cross-sectional study using analytical methods between January 1, 2020, and January 1,

APA, Harvard, Vancouver, ISO, and other styles

42

Chue, Pierre S., Peter D'Hoore, and J. Michael Ramstack. "Sustained drug delivery optimizes long-term treatment of patients with schizophrenia." Acta Neuropsychiatrica 16, no. 6 (2004): 319–25. http://dx.doi.org/10.1111/j.0924-2708.2004.00100.x.

Full text

Abstract:

Chronic disorders such as schizophrenia require long-term treatment programs in order to maintain patients at the lowest level of symptomatology, reduce the likelihood of psychotic relapse, and support achievement of remission and recovery. Evidence suggests that treatment with long-acting injectable antipsychotics reduces the impact of partial compliance and provides predictable release of medication, assuring continuous therapeutic coverage. Until recently, only conventional antipsychotic agents were available in long-acting formulations, thereby foregoing the advantages of the atypical clas

APA, Harvard, Vancouver, ISO, and other styles

43

Saklad, Stephen R., Tiffany-Jade Kreys, and Stephanie Phan. "Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia." Mental Health Clinician 5, no. 4 (2015): 149–61. http://dx.doi.org/10.9740/mhc.2015.07.149.

Full text

Abstract:

ABSTRACT Introduction Patients with schizophrenia often relapse as a result of medication nonadherence. Methods Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion This manuscript reviews important clinical informa

APA, Harvard, Vancouver, ISO, and other styles

44

Guillena, Samuel-Leopoldo Romero, and Beatriz-Oda Plasencia García de Diego. "68 Cognitive Impairment in Schizophrenia. First-generation Long-acting Antipsychotics versus Aripiprazole Long-acting Injectable." CNS Spectrums 24, no. 1 (2019): 211–12. http://dx.doi.org/10.1017/s1092852919000531.

Full text

Abstract:

AbstractStudy ObjectivesTo assess differences in cognitive impairment in a group of patients with schizophrenia receiving first-generation long-acting antipsychotics (FG-LAI) versus Aripiprazole long-actinginjectable (ALAI).MethodA descriptive, cross-sectional, multi-centerstudy.Study sample: 28 outpatients with stable schizophrenia (18 men and 10 women) with ages ranging from 22 to 64years.Inclusion criteria were: Clinically stable patients with a diagnosis of schizophrenia (according to DSM-5 criteria) and without any changes to their antipsychotic or antidepressant therapy in the last six m

APA, Harvard, Vancouver, ISO, and other styles

45

Messina, Antonino, Fabrizio Bella, Giuliana Maccarone, Alessandro Rodolico, and Maria Salvina Signorelli. "Neutrophil–Lymphocyte Ratio Values in Schizophrenia: A Comparison between Oral and Long-Acting Antipsychotic Therapies." Brain Sciences 14, no. 6 (2024): 602. http://dx.doi.org/10.3390/brainsci14060602.

Full text

Abstract:

Background: Schizophrenia is a mental disorder affecting approximately 0.32% of the global population, according to the World Health Organization. Antipsychotic medications are used to treat this condition by inhibiting D2 dopamine and 5HT2 serotonin receptors. The selection of the appropriate mode of delivery for these drugs is based on factors such as patient adherence, clinical presentation, and patient preferences. However, additional drivers of treatment selection are required in clinical practice. Mounting evidence suggests that neuroinflammation plays a crucial role in the pathogenesis

APA, Harvard, Vancouver, ISO, and other styles

46

Gautam, Prabin, Titilola Osoba, and Shalina Mitchell. "Procyclidine Use with Long-Acting Injectable Antipsychotics." BJPsych Open 11, S1 (2025): S132. https://doi.org/10.1192/bjo.2025.10367.

Full text

Abstract:

Aims: Our aim was to review if procyclidine is being prescribed as per BNF guidelines at DGS CMHT. As per BNF guidelines, procyclidine is recommended to be initiated at 2.5 mg of procyclidine three times per day increasing by 2.5 mg daily until symptoms are relieved. The effective maintenance dose is usually 10–30 mg procyclidine per day. After a period of 3–4 months of therapy, procyclidine should be withdrawn and the patient should be observed to see whether the neuroleptic-induced extrapyramidal symptoms recur.Methods: A retrospective clinical audit was conducted on 36 patients receiving lo

APA, Harvard, Vancouver, ISO, and other styles

47

Hsu, Hsiao-Fen, Chia-Chan Kao, Ti Lu, Jeremy C. Ying, and Sheng-Yu Lee. "Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services." Journal of Clinical Medicine 8, no. 6 (2019): 823. http://dx.doi.org/10.3390/jcm8060823.

Full text

Abstract:

The current study explored the differences in the effectiveness of first and second generation long-acting injections and orally administered antipsychotics in reducing the rehospitalization rate among patients with schizophrenia receiving home care services in a medical center in Southern Taiwan. Longitudinal data between 1 January 2006, and 31 December 2015, were collected retrospectively. Patients were classified into three treatment groups: First generation antipsychotic (FGA) long-acting injection (LAI), second generation antipsychotic long-acting injection (SGA) (LAI), and oral antipsych

APA, Harvard, Vancouver, ISO, and other styles

48

Saiz, P. A. "Impact of long-acting injectable antipsychotics on the illness progression in schizophrenia." European Psychiatry 30, S2 (2015): S50. http://dx.doi.org/10.1016/j.eurpsy.2015.09.141.

Full text

Abstract:

Several data suggest an association between repeated psychotic episodes in patients with schizophrenia and poor outcomes on the course of the illness, including worse psychosocial functioning and quality of life, deterioration and stigma. However, there is strong evidence showing antipsychotic efficacy for relapse prevention in chronic and first-episode patients. Non-adherence and partial adherence to antipsychotic treatment is a common feature that has been detected in half or more patients with schizophrenia. The use of long-acting injectable antipsychotics (LAIs) is a valuable treatment opt

APA, Harvard, Vancouver, ISO, and other styles

49

Olivares, José M., Beatriz Pinal, and Carmen Cinos. "Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia." Neuropsychiatry 1, no. 3 (2011): 275–89. http://dx.doi.org/10.2217/npy.11.24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Miron, Ana Aliana, Paula Simina Petric, Andreea Teodorescu, Petru Ifteni, Gabriela Chele, and Andreea Silvana Szalontay. "Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study." Brain Sciences 13, no. 2 (2023): 173. http://dx.doi.org/10.3390/brainsci13020173.

Full text

Abstract:

Schizophrenia is a chronic, invalidating, and polymorphic disease, characterized by relapses and remission periods. The main treatment option in schizophrenia are antipsychotics, administered as an oral or as a long-acting injectable (LAI) formulation. Although international guidelines rarely recommend it, mood stabilizers (MS) and/or benzodiazepines (BZD) are frequently prescribed as adjunctive therapy in schizophrenia patients for various reasons. This is an observational, cross-sectional study including stabilized schizophrenia patients. A total of 315 patients were enrolled. Of these, 77 p

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!